Skip to main content

Table 1 Baseline characteristics of patients

From: Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer

Characteristic

Age, Median (Range)

66 (49–86)

Race, Number (Percentage)

 White

41 (68.3)

 Black

17 (28.3)

 Asian

1 (1.7)

 Native American

1 (1.7)

PSA, Median (Range)

5.83 (0.5–13.53)

Stage, Number (Percentage)

 T1c

47 (78.3)

 T2a

11 (18.3)

 T2b

2 (3.3)

Number of Biopsy Cores, Median (Range)

12 (2–26)

Number of Positive Cores, Median (Range)

3 (1–10)

Gleason Score, Number (Percentage)

 6

24 (40)

 7

36 (60)

Median Follow-Up, Months

27.6